Fritextsökning
Innehållstyper
-
Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients
In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.
-
Extremely high sample throughput rates
Precision and reliability in automated liquid handling
-
Meeting with focus on South Korea and Japan’s life sciences
Large, complex and exciting – this is how Britta Stenson, Business Sweden, describes the life science markets of Japan and South Korea, which took centre stage ...
-
Bought a tablet factory – and built his own empire
. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.
-
BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”
he also highlights a study that points out that companies with a high degree of interaction with other companies achieve greater success.
-
Rapid developments in AI – “All stakeholders are struggling to understand it”
Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, ke...
-
A new malaria vaccine offers hope but much more research is still needed
There has long been no vaccine against malaria, but there have been breakthroughs in recent years. However, it is still unclear how we become immune to the mala...
-
Ny vd i Active biotech
Active biotechs styrelse har utsett bolagets nuvarande forskningschef till ny vd.
-
Anna Törner: The minute between life and death
“I have never told anyone about this day that happened more than 20 years ago. But I sometimes reflect on what happened, on what might have happened. When I try...
-
“We are Europe’s hotspot in life science”
The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees ...
-
Anna Törner: The clinical trial – Periscope to reality
What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.
-
Active Biotech tar in pengar
Tar in 55 miljoner till verksamheten genom företrädesemission.
-
Orosmoln för Active Biotech
Avbryter studier med högre doser av laquinimod, bolagets enda kvarvarande kliniska projekt.
-
Amorphous materials take centre stage when Orexo develops new formulations
Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive ...
-
Just four weeks to a concept for an emergency ventilator
The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...
-
Ready-to-install solutions for the lab-on-a-chip
Design for manufacturing lab-on-a-chip devices Reducing time-to-market together
-
The TFS family is growing
TFS HealthScience is a European based CRO company with broad expertise and experiences in the biotech and pharmaceutical sector. The company is growing and the ...
-
He is zooming in on topical preparations
According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting ap...
-
Marie Gårdmark: Potential step change – EU regulators get to play with data
to the outcome of the pilot to hopefully then understand if “in house” analyses actually will add value.
-
Failed to read the fine print – lost his life’s work
A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...
-
Neanderthal genes and Nobel Prize in a popular lecture at Bioscience
An inherited gene variant from our ”evolutionary cousins” – the extinct Neanderthals – may affect how our bodies break down certain drugs. “It’s only a matter o...
-
The fast route to a safe insulin pen
Diabetes is on the rise worldwide with around ten million people developing the disease every year. Demand for insulin pens allowing patients to self-medicate i...
-
Active Biotech avbryter tasquinimod
Avslutar flaggskeppsprojektet tasquinimod – nu väntar personalminskningar.
-
“An entire industry is about to be wiped out”
According to Jennie Ekbeck, CEO of Umeå Biotech Incubators, Sweden risks not having any small diagnostic companies left in five years.
BREAKING